Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 Uncommon EGFR exon 19del | patients with uncommon EGFR exon 19del |
| |
| Cohort 2 EGFR exon 19delins | patients with EGFR exon 19delins |
| |
| Cohort 3 EGFR exon 18del | patients with EGFR exon 18del |
| |
| Cohort 4 Common Uncommon Point Mutations | patients with common uncommon point mutations |
| |
| Cohort 5 Rare Uncommon Point Mutations | patients with rare uncommon point mutations |
| |
| Cohort 6 Compound Mutations Uncommon With Uncommon | patients with compound mutations uncommon with uncommon |
| |
| Cohort 7 Compound Mutations Uncommon With Common |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Third-generation EGFR-TKI | Drug | Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc. |
|
| Measure | Description | Time Frame |
|---|---|---|
| PFS | Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first) | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| OS | Defined as the time from the start of treatment to the death of the subject due to any cause. | 5 years |
| ORR | Defined as the proportion of subjects achieving a complete remission (CR) or partial remission (PR) among all subjects. |
Not provided
Inclusion Criteria:
18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
Exclusion Criteria:
Not provided
Not provided
Not provided
Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yongchang Zhang, MD | Contact | +8613873123436 | 7+861383123436 | zhangyongchang@csu.edu.cn |
| Nong Yang, MD | Contact | +8613055193557 | +8613873123436 | yangnong0217@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Yongchang Zhang, MD | Hunan Cancer Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yongchang Zhang | Recruiting | Changsha | Hunan | 410013 | China |
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
patients with compound mutations uncommon with common |
|
| EGFR-TKI | Drug | All EGFR-TKI |
|
| 5 years |
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |